Form 8-K/A BIOMARIN PHARMACEUTICAL For: Apr 27
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
BioMarin completes acquisition of Amicus Therapeutics
July 13, 2026 4:15 PM EDTBioMarin Pharmaceutical Inc. (NASDAQ: BMRN) has completed its acquisition of Amicus Therapeutics, Inc., according to a filing with the U.S. Securities and Exchange Commission.
BioMarin filed a Current Report on Form 8-K on April 27, 2026, disclosing the consummation of the deal. Under the terms... More
